Hepsin and prostate cancer

被引：61

作者：

Wu, Qingyu ^{[1
,2
]}

Parry, Gordon ^{[3
]}

机构：

[1] Cleveland Clin Fdn, Lerner Res Inst, Dept Mol Cardiol, Cleveland, OH 44195 USA

[2] Cleveland Clin Fdn, Lerner Res Inst, Dept Hypertens & Nephrol, Cleveland, OH 44195 USA

[3] Berlex Biosci, Dept Canc Res, Richmond, CA 94806 USA

来源：

FRONTIERS IN BIOSCIENCE-LANDMARK | 2007年 / 12卷

关键词：

hepsin; prostate cancer; type II transmembrane serine protease; drug target; review;

D O I：

10.2741/2447

中图分类号：

Q5 [生物化学]; Q7 [分子生物学];

学科分类号：

071010 ; 081704 ;

摘要：

Hepsin is a membrane serine protease expressed in several human tissues including the liver, kidney, prostate, and thyroid. The physiological function of hepsin remains unknown. In vitro studies have shown that hepsin activates blood clotting factors VII, XII, and IX, prourokinase (pro-uPA), and pro-hepatocyte growth factor (pro-HGF). Recently, hepsin has been identified as one of the most up-regulated genes in prostate cancer. The hepsin up-regulation appears to correlate with the disease progression. In a mouse model of prostate cancer, hepsin overexpression promotes cancer progression and metastasis. In culture, anti-hepsin antibodies inhibited the invasion of human prostate cancer cells. This review will outline the molecular biology and biochemistry of hepsin and highlight recent data of hepsin in prostate cancer.

引用

页码：5052 / 5059

页数：8

共 84 条

[1]

Abdulkadir Sarki A, 2005, Future Oncol, V1, P351, DOI 10.1517/14796694.1.3.351

[2]

BETSUNOH H, 2007, CANCER SCI, V12, P12

[3] Gene expression profile of ovarian serous papillary carcinomas: identification of metastasis-associated genes [J].

Bignotti, Eliana ;

Tassi, Renata A. ;

Calza, Stefano ;

Ravaggi, Antonella ;

Bandiera, Elisabetta ;

Rossi, Elisa ;

Donzelli, Carla ;

Pasinetti, Brunella ;

Pecorelli, Sergio ;

Santin, Alessandro D. .

AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 2007, 196 (03) :245-246

[4] Met, metastasis, motility and more [J].

Birchmeier, C ;

Birchmeier, W ;

Gherardi, E ;

Vande Woude, GF .

NATURE REVIEWS MOLECULAR CELL BIOLOGY, 2003, 4 (12) :915-925

[5] Analysis of candidate genes for prostate cancer [J].

Burmester, JK ;

Suarez, BK ;

Lin, JH ;

Jin, CH ;

Miller, RD ;

Zhang, KQ ;

Salzman, SA ;

Reding, DJ ;

Catalona, WJ .

HUMAN HEREDITY, 2004, 57 (04) :172-178

[6] Hypertension in mice lacking the proatrial natriuretic peptide convertase corin [J].

Chan, JCY ;

Knudson, O ;

Wu, FY ;

Morser, J ;

Dole, WP ;

Wu, QY .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2005, 102 (03) :785-790

[7] Hepsin and maspin are inversely expressed in laser capture microdissectioned prostate cancer [J].

Chen, ZX ;

Fan, ZB ;

McNeal, JE ;

Nolley, R ;

Caldwell, MC ;

Mahadevappa, M ;

Zhang, ZM ;

Warrington, JA ;

Stamey, TA .

JOURNAL OF UROLOGY, 2003, 169 (04) :1316-1319

[8] c-Met as a target for human cancer and characterization of inhibitors for therapeutic intervention [J].

Christensen, JG ;

Burrows, J ;

Salgia, R .

CANCER LETTERS, 2005, 225 (01) :1-26

[9] Plasminogen activation and cancer [J].

Dano, K ;

Behrendt, N ;

Hoyer-Hansen, G ;

Johnsen, M ;

Lund, LR ;

Ploug, M ;

Romer, J .

THROMBOSIS AND HAEMOSTASIS, 2005, 93 (04) :676-681

[10] Delineation of prognostic biomarkers in prostate cancer [J].

Dhanasekaran, SM ;

Barrette, TR ;

Ghosh, D ;

Shah, R ;

Varambally, S ;

Kurachi, K ;

Pienta, KJ ;

Rubin, MA ;

Chinnaiyan, AM .

NATURE, 2001, 412 (6849) :822-826

← 1 2 3 4 5 6 7 8 9 →